Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.

Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Kliger AS; Frequent Hemodialysis Network (FHN) Trial Group.

J Am Soc Nephrol. 2012 Apr;23(4):727-38. doi: 10.1681/ASN.2011070688. Epub 2012 Feb 23.

2.

Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.

Copland M, Komenda P, Weinhandl ED, McCullough PA, Morfin JA.

Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Review.

PMID:
27772640
3.

Control of parathyroid function in patients with a short history of hemodialysis.

Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.

Ther Apher Dial. 2005 Feb;9(1):39-43.

PMID:
15828904
4.

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

Block GA, Hulbert-Shearon TE, Levin NW, Port FK.

Am J Kidney Dis. 1998 Apr;31(4):607-17.

PMID:
9531176
5.
6.

Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.

Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP.

Clin Nephrol. 1996 Feb;45(2):111-9.

PMID:
8846523
7.

Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.

Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB; Collaborative Study Group.

Am J Kidney Dis. 2013 May;61(5):759-66. doi: 10.1053/j.ajkd.2012.11.041. Epub 2013 Jan 29.

PMID:
23369827
8.

[The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].

Zwiech R, Dryja P, Łacina D, Króliczak V, Chrul S, Kacprzyk F.

Wiad Lek. 2011;64(1):9-14. Polish.

PMID:
21812357
9.

The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial.

Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B.

Hemodial Int. 2010 Apr;14(2):174-81. doi: 10.1111/j.1542-4758.2009.00418.x. Epub 2009 Dec 22.

PMID:
20041960
10.

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.

Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM.

J Bone Miner Res. 2005 May;20(5):764-72. Epub 2004 Dec 20.

11.

Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients.

d'Almeida Filho EJ, da Cruz EA, Hoette M, Ruzany F, Keen LN, Lugon JR.

Sao Paulo Med J. 2000 Nov 9;118(6):179-84.

12.

Short daily and nocturnal hemodialysis: new therapies for a new century?

Rocco MV.

Saudi J Kidney Dis Transpl. 2009 Jan;20(1):1-11.

13.

Calcium and phosphate balance with quotidian hemodialysis.

Lindsay RM, Alhejaili F, Nesrallah G, Leitch R, Clement L, Heidenheim AP, Kortas C.

Am J Kidney Dis. 2003 Jul;42(1 Suppl):24-9.

PMID:
12830440
14.

Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.

Toussaint ND, Polkinghorne KR, Kerr PG, Somerville CA, Agar JW.

Hemodial Int. 2007 Apr;11(2):217-24.

PMID:
17403174
15.

Adherence to treatment and hospitalization risk in hemodialysis patients.

Vaiciuniene R, Kuzminskis V, Ziginskiene E, Skarupskiene I, Bumblyte IA.

J Nephrol. 2012 Sep-Oct;25(5):672-8. doi: 10.5301/jn.5000038.

PMID:
21983989
16.

Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration.

Al-Hejaili F, Kortas C, Leitch R, Heidenheim AP, Clement L, Nesrallah G, Lindsay RM.

J Am Soc Nephrol. 2003 Sep;14(9):2322-8.

17.

Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.

Ahmadi F, Shamekhi F, Lessan-Pezeshki M, Khatami MR.

Saudi J Kidney Dis Transpl. 2012 Sep;23(5):934-8. doi: 10.4103/1319-2442.100865.

18.

Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients.

Lorenzo V, Martín M, Rufino M, Jiménez A, Malo AM, Sanchez E, Hernández D, Rodríguez M, Torres A.

Am J Kidney Dis. 2001 Jun;37(6):1260-6.

PMID:
11382697
19.

Survival with three-times weekly in-center nocturnal versus conventional hemodialysis.

Lacson E Jr, Xu J, Suri RS, Nesrallah G, Lindsay R, Garg AX, Lester K, Ofsthun N, Lazarus M, Hakim RM.

J Am Soc Nephrol. 2012 Apr;23(4):687-95. doi: 10.1681/ASN.2011070674. Epub 2012 Feb 23.

20.

Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis.

Garg AX, Suri RS, Eggers P, Finkelstein FO, Greene T, Kimmel PL, Kliger AS, Larive B, Lindsay RM, Pierratos A, Unruh M, Chertow GM; Frequent Hemodialysis Network Trial Investigators.

Kidney Int. 2017 Mar;91(3):746-754. doi: 10.1016/j.kint.2016.10.033. Epub 2017 Jan 13.

Supplemental Content

Support Center